User profiles for Ivan C.H. Au
 | Ivan Chi Ho AuPhD candidate, University of Hong Kong Verified email at hku.hk Cited by 804 |
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two …
SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two …
[HTML][HTML] Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the clinical …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the clinical …
[HTML][HTML] Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected, …
clinical management and isolation of patients with COVID-19. We evaluated an unselected, …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of …
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation
To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir
in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected …
in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected …
[HTML][HTML] Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)
Background Evidence remains inconclusive on any significant benefits of remdesivir in patients
with mild-to-moderate COVID-19. This study explored the disease progression, various …
with mild-to-moderate COVID-19. This study explored the disease progression, various …
Validity and reliability of a measurement of objective functional impairment in lumbar degenerative disc disease: the timed up and go (TUG) test
…, NR Smoll, MV Corniola, H Joswig, I Chau… - …, 2016 - journals.lww.com
BACKGROUND: There are few objective measures of functional impairment to support clinical
decision making in lumbar degenerative disc disease (DDD). OBJECTIVE: We present …
decision making in lumbar degenerative disc disease (DDD). OBJECTIVE: We present …
Optimal timing of remdesivir initiation in hospitalized patients with coronavirus disease 2019 (COVID-19) administered with dexamethasone
Background Evidence is lacking about any additional benefits of introducing remdesivir on
top of dexamethasone, and the optimal timing of initiation. Methods In a territory-wide cohort …
top of dexamethasone, and the optimal timing of initiation. Methods In a territory-wide cohort …
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study
Background and Aim To investigate and quantify the risks of AKI and ALI associated with
remdesivir use, given the underlying diseases of SARS‐CoV‐2 infection. Methods This self‐…
remdesivir use, given the underlying diseases of SARS‐CoV‐2 infection. Methods This self‐…